Literature DB >> 1940798

Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals.

P J Barr1, K M Green, H L Gibson, I C Bathurst, I A Quakyi, D C Kaslow.   

Abstract

Pfs25 is a sexual stage antigen of Plasmodium falciparum that is expressed on the surface of zygote and ookinete forms of the parasite. Monoclonal antibodies directed against native Pfs25 can block completely the development of P. falciparum oocysts in the midgut of the mosquito vector. Thus, this 25-kD protein is a potential vaccine candidate for eliciting transmission-blocking immunity in inhabitants of malaria endemic regions. We have synthesized, by secretion from yeast, a polypeptide analogue of Pfs25 that reacts with conformation-dependent monoclonal antibodies, and elicits transmission-blocking antibodies when used to immunize mice and monkeys in conjunction with a muramyl tripeptide adjuvant. Our results suggest the further evaluation of recombinant DNA-derived Pfs25 in transmission-blocking vaccination studies in humans.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1940798      PMCID： PMC2118997          DOI： 10.1084/jem.174.5.1203

Source DB:  PubMed          Journal:  J Exp Med        ISSN： 0022-1007            Impact factor:   14.307


  11 in total

1.  Safety and immunogenicity of a Plasmodium vivax sporozoite vaccine.

Authors:  D M Gordon; T M Cosgriff; I Schneider; G F Wasserman; W R Majarian; M R Hollingdale; J D Chulay
Journal:  Am J Trop Med Hyg       Date:  1990-06       Impact factor: 2.345

2.  The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies.

Authors:  I A Quakyi; R Carter; J Rener; N Kumar; M F Good; L H Miller
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

Review 3.  Regulated transcriptional systems for the production of proteins in yeast: regulation by carbon source.

Authors:  J R Shuster
Journal:  Biotechnology       Date:  1989

4.  Immunogenicity of recombinant Plasmodium falciparum SERA proteins in rodents.

Authors:  P J Barr; J Inselburg; K M Green; J Kansopon; B K Hahm; H L Gibson; C T Lee-Ng; D J Bzik; W B Li; I C Bathurst
Journal:  Mol Biochem Parasitol       Date:  1991-03       Impact factor: 1.759

5.  Priming of CD4+ T cells specific for conserved regions of human immunodeficiency virus glycoprotein gp120 in humans immunized with a recombinant envelope protein.

Authors:  S Abrignani; D Montagna; M Jeannet; J Wintsch; N L Haigwood; J R Shuster; K S Steimer; A Cruchaud; T Staehelin
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

6.  Alpha-factor-directed synthesis and secretion of mature foreign proteins in Saccharomyces cerevisiae.

Authors:  A J Brake; J P Merryweather; D G Coit; U A Heberlein; F R Masiarz; G T Mullenbach; M S Urdea; P Valenzuela; P J Barr
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

7.  Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus.

Authors:  D C Kaslow; S N Isaacs; I A Quakyi; R W Gwadz; B Moss; D B Keister
Journal:  Science       Date:  1991-05-31       Impact factor: 47.728

8.  Characterization of recombinant human epidermal growth factor produced in yeast.

Authors:  C George-Nascimento; A Gyenes; S M Halloran; J Merryweather; P Valenzuela; K S Steimer; F R Masiarz; A Randolph
Journal:  Biochemistry       Date:  1988-01-26       Impact factor: 3.162

9.  Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity.

Authors:  G N Gill; T Kawamoto; C Cochet; A Le; J D Sato; H Masui; C McLeod; J Mendelsohn
Journal:  J Biol Chem       Date:  1984-06-25       Impact factor: 5.157

10.  Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito.

Authors:  A N Vermeulen; T Ponnudurai; P J Beckers; J P Verhave; M A Smits; J H Meuwissen
Journal:  J Exp Med       Date:  1985-11-01       Impact factor: 14.307
View more
  92 in total

1.  Structural and antigenic properties of merozoite surface protein 4 of Plasmodium falciparum.

Authors:  L Wang; C G Black; V M Marshall; R L Coppel
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies.

Authors:  C A Lobo; R Dhar; N Kumar
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

3.  A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies.

Authors:  A W Stowers; D B Keister; O Muratova; D C Kaslow
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 4.  Vaccines for malaria: how close are we?

Authors:  Mahamadou A Thera; Christopher V Plowe
Journal:  Annu Rev Med       Date:  2011-11-10       Impact factor: 13.739

5.  Blocking effect of a monoclonal antibody against recombinant Pvs25 on sporozoite development in Anopheles sinensis.

Authors:  Sung-Ung Moon; Hyung-Hwan Kim; Tong-Soo Kim; Kyung-Mi Choi; Chang-Mi Oh; Yong-Joo Ahn; Seo-Kyoung Hwang; Youngjoo Sohn; E-Hyun Shin; Hyuck Kim; Hyeong-Woo Lee
Journal:  Clin Vaccine Immunol       Date:  2010-06-16

6.  In vitro generation of Plasmodium falciparum ookinetes.

Authors:  Viengngeun Bounkeua; Fengwu Li; Joseph M Vinetz
Journal:  Am J Trop Med Hyg       Date:  2010-12       Impact factor: 2.345

7.  Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.

Authors:  Cevayir Coban; Ken J Ishii; Anthony W Stowers; David B Keister; Dennis M Klinman; Nirbhay Kumar
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations.

Authors:  Cevayir Coban; Mario T Philipp; Jeanette E Purcell; David B Keister; Mobolaji Okulate; Dale S Martin; Nirbhay Kumar
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum.

Authors:  D C Kaslow; I C Bathurst; T Lensen; T Ponnudurai; P J Barr; D B Keister
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

10.  A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses.

Authors:  R Mark Jones; Jessica A Chichester; Slobodanka Manceva; Sandra K Gibbs; Konstantin Musiychuk; Moneim Shamloul; Joey Norikane; Stephen J Streatfield; Marga van de Vegte-Bolmer; Will Roeffen; Robert W Sauerwein; Vidadi Yusibov
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.